We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Vircell S.L.

Vircell is a biotechnology company specialized in the development and production of ready-to-use reagents for the dia... read more Featured Products: More products

Download Mobile App





Vircell Presents Latest Offerings and Products in Diagnostic Testing

By LabMedica International staff writers
Posted on 12 Nov 2024

Vircell (Granada, Spain) is attending this year’s MEDICA where the company is highlighting its latest offerings as well as upcoming products. More...

At MEDICA 2024, Vircell is highlighting the VirClia Lotus instrument based on its monotest technology to process infectious disease immunoassays for human diagnostic applications. VirClia Lotus accepts any combination of samples and reagents, regardless of the instrument status. Even while running, it remains accessible for reagent and sample addition. VirClia Lotus’ built-in scanner allows for full traceability of both samples and strips, avoiding clerical errors. This true monotest solution allows the laboratory to run low-volume infectious serology tests daily, alongside the laboratory routine. VirClia Lotus unifies all the parameters typically performed with ELISA, IFA or rapid tests in just one chemiluminescent immunoassay (CLIA) system.

Among its wide range of rapid tests, Vircell is showcasing its new ASPERGILLUS GALACTOMANNAN Ag VIRCLIA MONOTEST for the detection of invasive aspergillosis as an aid for the early diagnosis of this life-threatening disease. This sandwich CLIA is intended for the detection of Aspergillus galactomannan antigen in serum, plasma and human bronchoalveolar lavage (BAL) samples. Vircell is also showcasing the HELICOBACTER PYLORI Ag VIRCLIA MONOTEST, an innovative, fully automated single-test format for detecting H. pylori antigen in stool samples. This sandwich CLIA test simplifies sample preparation by eliminating the need for centrifugation, using a tube with a built-in filter instead.

Additionally, Vircell is highlighting the INVASIVE CANDIDIASIS (CAGTA) VIRCLIA IgG MONOTEST for the early detection of invasive candidiasis (IC) that discriminates infection from colonization. This indirect CLIA is intended to detect IgG antibodies against antigens located on the cell wall surface of the micelium of Candida albicans (CAGTA, Candida albicans germ tube antibody) in human serum/plasma. Visitors to the Vircell booth can also learn about the company’s CLIAs to detect antibodies against hepatitis E virus in human serum or plasma samples. These assays offer a complete solution as an aid in the diagnosis of hepatitis E: HEV IgM, HEV IgG, and HEV IgG avidity.

Related Links:
Vircell


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Rapid Flu Test
Influenza A&B Rapid Test Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.